Reviro 300mg (Tenofovir Disoproxil Fumarate)

DESCRIPTION

Tenofovir is sold under the trade name Reviro and belongs to anticancer drugs, it is a medication used for treatment of chronic hepatitis B and to prevent and treat HIV/AIDS. Reviro show activity against HIV-1 reverse transcriptase.

The drug require for the use with other antiretrovirals. Reviro is a prescription drugs given under supervision of doctor or pharmacist.

INDICATION

In adult Reviro is used to treat in patients suffering chronic hepatitis B and decompensated liver diseases In adult and children 12yrs and >12yrs the drug Reviro is indicated for the treatment with combination of other antiretroviral agent to treat HIV-1 infection.

MECHANISM OF ACTION

When patient cell attack with HIV, then the HIV virus will take the cell under control of, then the virus grow repeated copies in the cell. For this process the virus needed an enzyme. When the activity of those enzymes is reduces the multiplication of HIV slows down. Reviro is nucleoside reverse transcriptase inhibitors (NRTIs). These inhibitor blocks the action of an HIV enzyme known as reverse transcriptase, in which the protein (enzyme) raises the speed of a chemical reaction. NRTIs interferes HIV from proliferation and reduces the amount of HIV in the body by stopping reverse transcriptase.

ADME

ABSORPTION

Rapid absorbed from GI tract, bioavailability (25%) The time to peak plasma concentration of Reviro is 1-2hrs.

DISTRIBUTION

the drug bounding of human serum protein is >1% and it is widely distributed into body tissue especially in kidney and liver ( volume of distribution is 1.2-1.3L/kg).

METABOLISM

TenofovirDisoproxil Fumarate is converted into Reviro through hydrolysis by cellular enzyme through phosphorylation. and to form active Reviro diphosphate . ELIMINATION: By active tubular secretion and glomerular Reviro excreted via urine. Half life of Reviro is 18hr.

DOSAGE MANAGEMENT

DOSAGE AND ADMINISTRATION

In adult 12yrs and older: 300mg If patient not able to shallow take oral powder formulation of 7.5 scoops In pediatric 2yrs and <12yrs : 8 mg recommended dose. If patient not able to shallow take oral powder formulation is 1 level scoop=1 g powder contains 40mg of Tenvirdisoporxil. ≥ 17kg Reviro dos available in different strengths 150, 200, 250 and 300mg. One tablet of Reviro 300mg, once daily without food, taken orally.

OVERDOSAGE

The drug has no severe adverse reaction for effect of higher dose and treatment provides of general supportive measures involves monitoring of evidence of toxicity and patients clinical status observation.

PRECAUTIONS

Hepatomegaly suffering patients or other severe factors for liver problem.Renal impairment. Pregnant women Patient Counselling Reviro may cause dizziness, do not drive or operate machinery.

Renal function and serum phosphate concentrations prior to therapy, 4 wkly in 1st wk, and then 3 mthly; hepatic function for several month following discontinuation. Determine HIV condition in all hepatitis B virus (HBV) infected patients before treatment. Allergy to Reviro or any other drug.Before inform with doctor about allergic to any drugs. Such as rash; hives; itching; Dyspnea; wheezing; cough; swelling of (face, lips, tongue, or throat); or any other signs.

If you had kidney or liver disease and taking colchicines then inform your doctor, he may stop the Reviro drug. Inform your doctor that you are pregnant or plan for pregnancy or breast feeding, while you infected with HIV or taking Reviro tablet avoid breast feed.

SIDE EFFECTS

COMMON EFFECTS

Mild nausea, stomach ache, insomnia, itching and rashes, Change in body shape (fat) Signs of allergic reaction Hives, Dyspnea, Swelling of (face,lips,throat,tongue) Severe hepatomegaly with steatosis Chest pain Wheezing Cold sore Fast heart rate Lumbar pain

DRUG INTERACTION

When Reviro interaction with didanosine and HIV-1 protease inhibitors then increase didanosine concentration and results in adverse effects like pancreatitis and neuropathy Interaction with HIV-1 protease inhibitors such as atazanavir will reduces atazanavir concentration while increase the Reviro concentrations

PREGNANCY 

Category B : Animal studies have shown an adverse effect in fetus, so sufficient and well-developed studies in pregnant women have failed give detail about a risk to the fetus in all trimester.

LACTATION

Reviro 300mg is preferably safe to use during breastfeeding. Limited information on the risk for the baby. Please consult with doctor

STORAGE 

The drug stored at 25°C(77°) and keep container tightly closed Dispense the drug only in original container

MISSED DOSE

If missed to take a dose ,leave the dose and take your next dose at the normal time or take it as soon as you remember and take your next dose at the normal time. Do not have the extra dose to make up for a missed dose. Please consult with the doctor.